NDAORALTABLETPriority Review
Approved
Jun 1964
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Data completeness
4/8 — Partial
Priority Review
AMICAR (aminocaproic acid) by Hikma. Approved for antifibrinolytic agent [epc]. First approved in 1964.
Drug data last refreshed 21h ago · AI intelligence enriched 3d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMICAR (aminocaproic acid) is an oral antifibrinolytic agent approved in 1964 that reduces fibrin breakdown to control excessive bleeding. It works by inhibiting plasminogen activation, thereby stabilizing blood clots in patients at risk of hemorrhage. The drug is indicated for antifibrinolytic therapy in conditions characterized by hyperfibrinolysis.
$0.06MPart D
LOE ApproachingMature product with declining spending and minimal claim volume indicates a contracting commercial footprint with reduced team and investment requirements.
Mechanism of Action
Pharmacologic Class:
Antifibrinolytic Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on AMICAR offers limited career growth due to zero linked job openings and a product approaching loss of exclusivity with minimal commercial footprint. This role is best suited for professionals seeking stability in a legacy product or transition planning experience rather than growth opportunities.
Brand ManagerProduct Manager
Worked on AMICAR at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.